Samenvatting
Background: Literature remains scarce on patients experiencing weight recurrence after initial adequate weight loss following primary bariatric surgery. Therefore, this study compared the extent of weight recurrence between patients who received a Sleeve Gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) after adequate weight loss at 1-year follow-up. Methods: All patients undergoing primary RYGB or SG between 2015 and 2018 were selected from the Dutch Audit for Treatment of Obesity. Inclusion criteria were achieving ≥ 20% total weight loss (TWL) at 1-year and having at least one subsequent follow-up visit. The primary outcome was ≥ 10% weight recurrence (WR) at the last recorded follow-up between 2 and 5 years, after ≥ 20% TWL at 1-year follow-up. Secondary outcomes included remission of comorbidities at last recorded follow-up. A propensity score matched logistic regression analysis was used to estimate the difference between RYGB and SG. Results: A total of 19.762 patients were included, 14.982 RYGB and 4.780 SG patients. After matching 4.693 patients from each group, patients undergoing SG had a higher likelihood on WR up to 5-year follow-up compared with RYGB [OR 2.07, 95% CI (1.89–2.27), p < 0.01] and less often remission of type 2 diabetes [OR 0.69, 95% CI (0.56–0.86), p < 0.01], hypertension (HTN) [OR 0.75, 95% CI (0.65–0.87), p < 0.01], dyslipidemia [OR 0.44, 95% CI (0.36–0.54), p < 0.01], gastroesophageal reflux [OR 0.25 95% CI (0.18–0.34), p < 0.01], and obstructive sleep apnea syndrome (OSAS) [OR 0.66, 95% CI (0.54–0.8), p < 0.01]. In subgroup analyses, patients who experienced WR after SG but maintained ≥ 20%TWL from starting weight, more often achieved HTN (44.7% vs 29.4%), dyslipidemia (38.3% vs 19.3%), and OSAS (54% vs 20.3%) remission compared with patients not maintaining ≥ 20%TWL. No such differences in comorbidity remission were found within RYGB patients. Conclusion: Patients undergoing SG are more likely to experience weight recurrence, and less likely to achieve comorbidity remission than patients undergoing RYGB.
| Originele taal-2 | Engels |
|---|---|
| Pagina's (van-tot) | 4351-4359 |
| Aantal pagina's | 9 |
| Tijdschrift | Surgical Endoscopy |
| Volume | 37 |
| Nummer van het tijdschrift | 6 |
| DOI's | |
| Status | Gepubliceerd - jun. 2023 |
| Extern gepubliceerd | Ja |
Financiering
The authors thank all surgeons, registrars, physician assistants and administrative nurses who registered patients in the DATO. This manuscript was written on behalf of the Dutch Audit for Treatment of Obesity (DATO) Research Group: L.M. de Brauw, MD, PhD (Spaarne Gasthuis, Haarlem); S.M.M. de Castro, MD, PhD (OLVG Hospital, Amsterdam); S.L. Damen, MD (Medical Centre Leeuwarden, Leeuwarden); A. Demirkiran, MD, PhD (Red Cross Hospital, Beverwijk); M. Dunkelgrün, MD, PhD (Franciscus Gasthuis & Vlietland, Rotterdam); I.F. Faneyte, MD, PhD (ZGT Hospital, Almelo & Hengelo); J.W.M. Greve, MD, PhD (Zuyderland Medical Centre, Heerlen); G. van ’t Hof, MD (Dutch Bariatric Centre South-West, Bergen op Zoom); I.M.C. Janssen, MD, PhD (Dutch Obesity Clinics, Zeist); E.H. Jutte, MD (Medical Centre Leeuwarden, Leeuwarden); R.A. Klaassen, MD (Maasstad Hospital, Rotterdam); E.A.G.L. Lagae, MD, PhD (ZorgSaam Zorggroep Zeeuws-Vlaanderen, Terneuzen); B.S. Langenhoff, MD, PhD (ETZ Hospital, Tilburg); R.S.L. Liem, MD (Groene Hart Hospital & Dutch Obesity Clinic, Gouda & The Hague); A.A.P.M. Luijten, MD, PhD (Máxima Medical Centre, Eindhoven); S.W. Nienhuijs, MD, PhD (Catharina Hospital, Eindhoven); R. Schouten, MD, PhD (Flevo Hospital, Almere); R.M. Smeenk, MD, PhD (Albert Schweitzer Hospital, Dordrecht); D.J. Swank, MD, PhD (Dutch Obesity Clinic West, Den Haag); M.J. Wiezer, MD, PhD (St. Antonius Hospital, Utrecht); W. Vening, MD, PhD (Rijnstate Hospital, Arnhem)
| Financiers | Financiernummer |
|---|---|
| St. Antonius Ziekenhuis |
Duurzame ontwikkelingsdoelstellingen van de VN
Deze output draagt bij aan de volgende duurzame ontwikkelingsdoelstelling(en)
